PP
AVIR icon

PDT Partners’s Atea Pharmaceuticals AVIR Stock Holding History

PDT Partners’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-65,954
Closed -$221K – 573
2023
Q1 		$221K Sell
65,954
-31
-0% -$126 0.03% 498
2022
Q4 		$317K Sell
65,985
-2,769
-4% -$14K 0.05% 475
2022
Q3 		$391K Buy
+68,754
New +$526K 0.06% 505
2022
Q2 		– Sell
-224,660
Closed -$1.62M – 954
2022
Q1 		$1.62M Sell
224,660
-53,827
-19% -$366K 0.14% 225
2021
Q4 		$2.49M Buy
+278,487
New +$4.34M 0.19% 197

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PDT Partners's AVIR Position: Q2 2023 in Review

PDT Partners sold out of Atea Pharmaceuticals (AVIR) in Q2 2023, closing a stake of 65,954 shares — an estimated $221K sold.

PDT Partners first reported a position in AVIR in Q4 2021 and held it in 5 quarters. The position peaked at $2.49M in Q4 2021. 133 funds tracked by Wall St. Rank hold AVIR as of Q2 2023.

  • PDT Partners reported no remaining Atea Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • PDT Partners sold 65,954 Atea Pharmaceuticals shares in Q2 2023, an estimated $221K.
  • PDT Partners first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • PDT Partners's Atea Pharmaceuticals position peaked at $2.49M in Q4 2021.
  • 133 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2023.

Based on PDT Partners's 13F filing for Q2 2023, filed 14 Aug 2023.